Pharma BD Deal Intelligence
AstraZeneca paid $1.05B for Amolyt Pharma to acquire eneboparatide, a long-acting PTH analog for chronic hypoparathyroidism—a rare endocrine disorder affecting ~200,000 patients globally with limited treatment options. The deal extended AZ's rare disease portfolio into endocrinology. The acquisition has since de-risked: eneboparatide met the primary endpoint of the Phase III CALYPSO trial (AstraZeneca, 17 March 2025), with 31.1% of patients achieving normalised serum calcium and independence from active vitamin D and oral calcium supplements at 24 weeks vs 5.9% on placebo.
AstraZeneca closes acquisition of Amolyt Pharma, expanding rare disease pipeline with eneboparatide for hypoparathyroidism
Eneboparatide met the primary endpoint of normalising serum calcium at 24 weeks in the Phase III CALYPSO trial (202 adults with chronic hypoparathyroidism).…
AstraZeneca strengthens rare disease portfolio with Amolyt Pharma acquisition valued at up to $1.05 billion including CVRs
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
AstraZeneca acquired Amolyt Pharma for $1.05B for eneboparatide for hypoparathyroidism.
30K US cases/yr · $2.8B US market (2024) · ~30,000 US patients living with acromegaly
Acromegaly is a rare hormonal disorder caused by excess growth hormone, usually from a pituitary adenoma. Current treatments include surgery, somatostatin analogues (octreotide, lanreotide), and GH receptor antagonists (pegvisomant). Significant unmet need remains for patients with inadequate biochemical control.
AZP-3813 is a peptide growth hormone receptor antagonist in preclinical development for acromegaly. It was part of Amolyt Pharma's rare endocrine pipeline acquired by AstraZeneca alongside lead program eneboparatide.
30K US cases/yr · $2.8B US market (2024) · ~30,000 US patients living with acromegaly
Acromegaly is a rare hormonal disorder caused by excess growth hormone, usually from a pituitary adenoma. Current treatments include surgery, somatostatin analogues (octreotide, lanreotide), and GH receptor antagonists (pegvisomant). Significant unmet need remains for patients with inadequate biochemical control.
AZP-3813 is a peptide growth hormone receptor antagonist in preclinical development for acromegaly. It was part of Amolyt Pharma's rare endocrine pipeline acquired by AstraZeneca alongside lead program eneboparatide.
10K US cases/yr · $1.5B Global Hypoparathyroidism Market (2028E)
Eneboparatide met Phase III Calypso primary endpoint: calcium normalization + independence from vitamin D/calcium. Well-tolerated. Novel PTH1R binding mechanism.
Ascendis Pharma TransCon PTH is main competitor. Natpara withdrawn. Eneboparatide offers differentiated PTH1R pharmacology via Alexion rare disease unit.
AstraZeneca completed $1.05B acquisition of Amolyt Pharma, gaining eneboparatide, long-acting PTH analog for hypoparathyroidism.
AZ advanced eneboparatide Phase 3 for hypoparathyroidism, targeting underserved rare endocrine disorder with once-daily dosing.
Eneboparatide met the primary endpoint in the Phase III CALYPSO trial (n=202): 31.1% of adults with chronic hypoparathyroidism achieved normalised serum calcium plus independence from active vitamin D and oral calcium supplements at 24 weeks vs 5.9% on placebo. Detailed 24-week data were presented at the 2026 European Congress of Endocrinology. Post-close validation of the lead asset acquired in the Amolyt deal.
Eneboparatide addresses clear hypoparathyroidism unmet need. Phase 3 with AZ rare disease infrastructure. Modest market but premium pricing expected.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Amolyt Pharma (this deal) | 2024 | $1.1B | 73 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2024 deals · AstraZeneca PLC deals · Rare Disease deals